https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46408 P < 0.001). An increase of one fast-food outlet corresponded with four additional cases of MI per 100 000 people per year (4.07, 95% confidence interval, 3.86-4.28). Conclusions: FFD was positively associated with incidence of MI in both rural and metropolitan areas of NSW. This relationship remained consistent after multivariate adjustment for standard cardiovascular risk factors, highlighting the importance of an individual's food environment as a potential contributor towards their health.]]> Wed 28 Feb 2024 14:47:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32642 Wed 24 Nov 2021 15:52:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30919 Wed 23 Feb 2022 16:07:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32965 Wed 19 Jan 2022 15:18:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29481 n = 144, 71%), followed by mouth spray (n = 84, 42%) and vaporiser (n = 83, 41%). Explanations for preferences (n = 134) most commonly cited convenience (n = 66; 49%). A total of 82% (n = 168) of respondents indicated that they had no trial-related concerns, but a small number volunteered concerns about adverse effects (n= 14) or wanted more information/advice (n = 8). Six respondents volunteered a belief that cannabis might cure cancer, while two wanted assurance of efficacy before participating in a trial. Conclusion: Justification of modes other than tablets/capsules and variable understanding about cannabis and trials will need addressing in trial-related information to optimise recruitment and ensure that consent is properly informed.]]> Wed 17 Nov 2021 16:32:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25807 Wed 09 Feb 2022 15:57:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45640 Wed 07 Feb 2024 15:02:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36334 0.05) at each sampling day. At day 7 post-transplant, 85.7% and 79.5% of the observed plasma concentrations were outside the recommended therapeutic range for obese and non-obese patients respectively, at day 30, 52.9% and 57.4%, and at 6 months, 18.7% and 27.5%. Conclusion: In the first week post-transplant, tacrolimus trough concentrations after standard mg/kg dosing post liver transplant appear to be corrected by total bodyweight. Obese patients have a similar number of trough plasma concentrations outside the therapeutic range compared to non-obese patients.]]> Wed 06 Apr 2022 14:03:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50159 Wed 05 Jul 2023 15:35:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50147 Wed 05 Jul 2023 13:57:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38904 P < 0.001), with higher rates of atrial fibrillation, hypertension and diabetes mellitus. Stroke complicating cardiac catheterisation was associated with an increased risk of readmission, with a significantly higher hazard of readmission for stroke noted. Despite minimal functional impairment based on modified Rankin score, stroke was associated with a significant risk of early and cumulative mortality. Stroke incidence remained stable over the study period despite changes in procedural practice. Conclusions: The incidence and functional severity of stroke remains low despite evolving procedural practice with a stable incidence over time despite changes in procedural practice; however, post-procedural stroke confirms an increased mortality hazard.]]> Wed 02 Mar 2022 12:28:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37180 Wed 01 Mar 2023 11:52:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46742 Tue 29 Nov 2022 15:25:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43725 30 years were four times more likely to have high knowledge of triggers for completing resuscitation plans (odds ratio 4.28 (95% confidence interval 1.54–11.89); P = 0.0053). Conclusion: Most junior doctors feel confident discussing and documenting resuscitation plans. There is a need to improve knowledge about legal obligations to follow completed resuscitation plans, and about when resuscitation plans should be completed to ensure they are completed with patients who are most at risk.]]> Tue 29 Aug 2023 11:43:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41786 Tue 23 Jan 2024 16:08:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37694 Tue 16 Mar 2021 17:30:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51649 70 years. Absolute rates of AVR increased from 3631 to 7277 with a significant 22% age-adjusted rise seen (1.9% increase per year (+0.26 per 100 000 per year; 95% confidence interval 0.19–0.34); P < 0.001). This trend was more pronounced in men than women and in those aged >80 years (+0.23 per 100 000 per year; P < 0.001). Proportion of mechanical AVR implanted fell from 38.4% to 8.6% (P < 0.001). A total of 2683 transcatheter aortic valve implantation (TAVI) procedures was performed in 2019, representing a 52% annual increase from 2014. BAV increased from 66 procedures in 2004 to 862 in 2019. Conclusion: Rates of AVR have increased significantly over the past 16 years, particularly in the elderly. Despite international guideline recommendations, fewer mechanical AVR are being used in younger cohorts. The uptake in TAVI rates might reflect evidence that suggests it is a safe alternative, at least in the medium term. BAV has also seen a resurgence during this time period.]]> Tue 12 Sep 2023 20:21:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47142 Tue 06 Feb 2024 15:06:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45700 2) to provide reperfusion to patients with STEMI involve a 12-lead electrocardiogram in the ambulance, discussion between cardiologist and paramedic, followed by pre-hospital thrombolysis (PHT) delivered in ambulance to appropriate patients >60 min from the cardiac catheterisation laboratories. Patients who can access the cardiac catheterisation laboratories within 60 min are treated with primary percutaneous coronary intervention (PCI). Aims: We have previously reported excellent 12-month outcomes for patients receiving PHT and the aim of the current analysis is to look at the long term outcomes. Methods: We assessed long-term all-cause mortality and major adverse cardiovascular events of STEMI patients undergoing PHT in our health district from August 2008 to August 2013 and compared with the primary PCI group. Results: One hundred and fifty (mean age: 62 ± 13 years, males: 76%, n = 114) patients were administered PHT and 334 patients (mean age: 65 ± 13 years, males: 75%, n = 251) underwent primary PCI during the study period. During a median follow up of 6.2 years (interquartile range: 4.8–7.4 years) all-cause mortality was 16% and 19% in the PHT and primary PCI groups respectively (P = 0.4). Conclusion: Our real-world experience shows that PHT followed by early transfer to a primary PCI-capable centre is an effective reperfusion strategy, with comparable results to primary PCI, and mortality benefits are sustained to more than 6 years.]]> Thu 29 Jun 2023 13:40:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30008 P < 0.001), warfarin and aspirin remained comparatively stable (38–34%, 22–20%), and those prescribed no medication declined (17–8%, P < 0.001). DOAC were prescribed to patients with lower CHA₂DS₂VASc scores than warfarin (3.6 vs 4.4; P = 0.005), lower HAS-BLED scores (1.7 vs 2.3; P < 0.01), higher glomerular filtration rates; 70 vs 63 ml/min; P = 0.002) and younger age (74 vs 77 years; P = 0.006). Nationally, warfarin prescriptions are higher in total numbers but increasing at a slower rate than DOAC, which increased 10-fold (101 158 in 2013, 1 095 985 in 2014). Conclusion: DOAC prescribing grew rapidly from 2013 to 2014, regionally and nationally. Warfarin prescriptions have remained stable, indicating that more patients are being appropriately anticoagulated for AF who previously were not. DOAC were found to be prescribed to patients with lower CHA₂DS₂VASc and HAS-BLED scores, younger age and higher glomerular filtration rates. Aspirin therapy remains over utilised in AF.]]> Thu 28 Oct 2021 13:03:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30174 Thu 28 Oct 2021 13:02:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34913 Thu 27 Jan 2022 15:59:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31999 Thu 27 Jan 2022 15:58:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:567 Thu 25 Jul 2013 09:10:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:186 500 ms and in seven of these causality was established based on a pre- or post-ECG with a QTc < 500 ms. Only 10% of the moclobemide cases had a heart rate (HR) > 100 beats per minute, making overcorrection of HR by Bazett's formula an unlikely cause of the findings. No cardiac arrythmias were observed other than one case of first-degree heart block. Conclusions Moclobemide prolongs the QT and QTc intervals in overdose and a 12-lead ECG should be done on all moclobemide deliberate self-poisonings. Continuous cardiac monitoring for what is otherwise a relatively benign overdose would appear to be an inappropriate use of resources but can be considered in patients with a QTc > 500 ms or with known risks for QT prolongation.]]> Thu 25 Jul 2013 09:09:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39023 Thu 21 Apr 2022 09:51:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37568 Thu 18 Feb 2021 16:08:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49342 Thu 11 May 2023 15:46:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34468 Thu 09 Dec 2021 11:03:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24803 Thu 09 Dec 2021 11:02:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46933 Thu 08 Dec 2022 13:52:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46920 Thu 08 Dec 2022 09:04:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29773 Haemophilus influenzae (NTHi) vaccine in chronic obstructive pulmonary disease (COPD): severe COPD, moderate-severe exacerbations as end-point and a threshold prevalence of NTHi in the study population. More data are needed to confirm parameters that influence clinical outcomes. Aims: The primary aim was to determine the efficacy of an oral NTHi vaccine (HI-164OV) in reducing the rate of exacerbations requiring systemic corticosteroids or hospitalisation in COPD. Secondary aims included effect on the proportion of patients experiencing such exacerbations, severity of infections and quality of life (St George Respiratory Questionnaire for COPD patients (SGRQ-C)). Methods: This multi-centre, double-blind, placebo-controlled study was conducted at 21 Australian sites for 9 months in 2011. Results: Three-hundred and twenty subjects with COPD, FEV₁ <60% predicted and ≥1 moderate-severe exacerbations in the previous 12 months were recruited. The primary and secondary end-points for the intention-to-treat population aged 40-88 years were not achieved, and only 5% of subjects had an H. influenzae-positive sputum sample. Subsequent exploratory analysis of patients <65years (91 subjects) indicated protection with respect to the primary and most of the secondary end-points, with SGRQ-C symptom scores lower at 3 and 6 months. Conclusion: Patients aged 40-88 years with moderate to severe COPD and low rates of H. influenzae-positive sputum were not protected against exacerbations by HI-1640V. Further studies are needed to confirm protection in subjects aged <65years. Older age and low colonisation rates appear to affect adversely response to this vaccine.]]> Thu 03 Feb 2022 12:18:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8234 Sat 24 Mar 2018 10:47:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8205 Sat 24 Mar 2018 10:45:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31402 Sat 24 Mar 2018 08:45:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31226 Sat 24 Mar 2018 08:43:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8357 Sat 24 Mar 2018 08:39:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8092 Sat 24 Mar 2018 08:34:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7174 Sat 24 Mar 2018 08:34:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7118 Sat 24 Mar 2018 08:34:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1120 Sat 24 Mar 2018 08:31:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1228 Sat 24 Mar 2018 08:28:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2292 Sat 24 Mar 2018 08:26:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13662 Sat 24 Mar 2018 08:25:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10302 Sat 24 Mar 2018 08:12:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10561 Sat 24 Mar 2018 08:08:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19923 Sat 24 Mar 2018 08:03:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20101 Sat 24 Mar 2018 08:00:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16968 Sat 24 Mar 2018 07:55:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19366 Sat 24 Mar 2018 07:52:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5581 Sat 24 Mar 2018 07:49:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5663 Sat 24 Mar 2018 07:44:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:272 Sat 24 Mar 2018 07:43:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:232 Sat 24 Mar 2018 07:42:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:389 Sat 24 Mar 2018 07:42:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28490 Helicobacter pylori infection known to be an important precipitant of peptic ulcer disease in patients receiving non-steroidal anti-inflammatory drug therapy. The prevalence of H. pylori positivity in patients undergoing PCI and receiving subsequent antiplatelet therapy is unknown. Aims: We sought to determine the prevalence and features associated with H. pylori positivity in patients undergoing PCI. Methods: All patients undergoing PCI between August 2008 and April 2009 were identified and assessed for H. pylori positivity with serological status determined by using a commercially supplied enzyme- linked immunosorbent assay. Results: A total of 245 patients undergoing PCI during the study period had samples obtained for H. pylori serology. Of these, 91 were positive for H. pylori serology (37%) and 148 were negative (60%) with six samples being equivocal (3%). Of those patients positive for H. pylori, 75% were on agents at admission known to promote or precipitate gastrointestinal haemorrhage. Patients positive for H. pylori tended to be older, with increased creatinine and more likely to be receiving proton pump inhibitor therapy. Conclusions: In an unselected cohort of patients undergoing PCI in a single centre, we detected a prevalence of H. pylori positivity in 37% of patients; this denotes a potentially treatable precipitant of haemorrhage in a considerable portion of patients receiving dual antiplatelet therapy after PCI. Further prospective study is required to determine if the presence of H. pylori positivity is associated with adverse events in terms of gastrointestinal and cardiac outcomes.]]> Sat 24 Mar 2018 07:39:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28270 Sat 24 Mar 2018 07:28:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26423 Sat 24 Mar 2018 07:27:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4856 Sat 24 Mar 2018 07:18:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24789 Clostridium difficile infection (CDI) continues to rise, whilst treatment remains problematic due to recurrent, refractory and potentially severe nature of disease. The treatment of C. difficile is a challenge for community and hospital-based clinicians. With the advent of an expanding therapeutic arsenal against C. difficile since the last published Australasian guidelines, an update on CDI treatment recommendations for Australasian clinicians was required. On behalf of the Australasian Society of Infectious Diseases, we present the updated guidelines for the management of CDI in adults and children.]]> Sat 24 Mar 2018 07:14:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25200 Sat 24 Mar 2018 07:14:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23782 Sat 24 Mar 2018 07:13:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23581 Sat 24 Mar 2018 07:12:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24158 Sat 24 Mar 2018 07:09:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38753 Mon 24 Jan 2022 10:35:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23876 3 g) admitted to a toxicology unit over 20 years. Cases were identified from a prospective database and data extracted included demographics, dose, coingestants, clinical effects, investigations, treatment and outcomes. Results: There were 36 acute metformin overdose cases. Median age 41 years old (15–68 years old); 25 were female. Median ingested dose was 10 g (interquartile range (IQR): 5–16.1 g; range: 3.5–50 g), with coingestants taken in 34 presentations. Gastrointestinal symptoms were present in 12/36, tachycardia in 10, bradycardia in three, hypotension in four and hypoglycaemia in eight. Hypotension and bradycardia were consistent with coingestants taken. Blood pH and lactate levels were available in 25/36. Median lowest pH was 7.35 (IQR: 7.28–7.38) and acidosis (pH < 7.35) occurred in 11/25. Median peak lactate was 3.9 mmol/L (IQR: 2.6–5.2 mmol/L). There was a statistical association between dose and lactate (r = 0.51; P = 0.01) and dose and pH (r = −0.70; P = 0.0001). Hyperlactataemia (lactate >2 mmol/L) without acidosis occurred in 10/25, and hyperlactataemia with acidosis in 11/25; five had lactic acidosis. The median time to peak lactate in 10 presentations with peak lactate >2 was 6 h (2–19 h). There were six intensive care unit admissions, one for lactic acidosis, and five related to coingestants. There were no deaths. Conclusion: Metformin overdose is characterised by hyperlactataemia and minor gastrointestinal effects, with a few large ingestions progressing to lactic acidosis. Coingestants are common and may dominate toxicity.]]> Mon 23 Jul 2018 12:56:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32766 Mon 23 Jul 2018 12:49:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47468 Mon 23 Jan 2023 10:58:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42332 STANDARD). Owing to the limitations of TTE, the ASIG developed a new screening algorithm (ASIG_PROPOSED) utilising a serum biomarker, NT-proBNP, in place of TTE, which has been shown to be equally accurate as the current algorithm. The aim of this study was to compare the cost of these two algorithms using different scenarios. The new algorithm resulted in significant yearly cost savings of between AU$42 913.35 and AU$84 570 in screening and diagnosis of an Australian cohort which, if extrapolated to the Australian population, would result in a yearly cost saving of between AU$367 066 and AU$725 564. There was no scenario in which the proposed algorithm did not result in a cost saving.]]> Mon 22 Aug 2022 13:42:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51100 Mon 21 Aug 2023 15:06:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34168 Mon 18 Feb 2019 13:59:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48933 Mon 17 Apr 2023 11:07:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47968 Mon 13 Feb 2023 15:58:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51576 Mon 11 Sep 2023 14:29:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54765 Mon 11 Mar 2024 15:01:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52267 Mon 09 Oct 2023 09:56:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42121 P = 0.012) and echocardiography (73.3% vs 97.7%, P = 0.004). Discharge follow up was significantly lower for the indigenous population (74.4% vs 87.4%, P = 0.034). Indigenous stroke patients were 15.8 years younger than non-indigenous subjects (56.8 vs 72.6 years old; P < 0.001). Indigenous patients were more likely to have stroke risk factors, including smoking (51.2% vs 15.0%; P < 0.001), diabetes mellitus (37.2% vs 16.8%, P = 0.003) and past history of cerebrovascular accident or transient ischaemic attack (50.2% vs 31.1%, P = 0.032). Conclusions: The investigation and post-discharge care of indigenous ischaemic stroke patients is inferior to non-indigenous patients. Indigenous patients within rural NSW have a higher prevalence of preventable disease, including those that confer a higher stroke risk. Further research is needed to investigate the cause of these discrepancies and to improving indigenous stroke care between hospitals and primary care providers.]]> Fri 26 Aug 2022 10:32:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54959 Fri 22 Mar 2024 15:34:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39926 Fri 22 Jul 2022 11:40:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44511 Fri 14 Oct 2022 09:11:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34691 Fri 12 Apr 2019 14:00:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46154 Fri 11 Nov 2022 19:05:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49189 Fri 05 May 2023 15:44:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26225 Fri 03 Dec 2021 10:33:00 AEDT ]]>